Heng Tong Choo
Directeur/Membre du Conseil chez Amaranth Medical, Inc.
Profil
Heng Tong Choo is currently the Director at Amaranth Medical, Inc. and the Executive Vice President at EDB Investments Pte Ltd.
Previously, he held positions as Director at Vanda Pharmaceuticals, Inc., Singapore Economic Development Board, S*BIO Pte Ltd., Artisan Pharma, Inc., Maccine Pte Ltd., Inviragen, Inc., and Trireme Medical LLC.
He also served as the Senior Vice President at Trireme Medical LLC.
Mr. Choo's education includes a graduate degree from The Trustees of Columbia University in The City of New York and Imperial College London.
Postes actifs de Heng Tong Choo
| Sociétés | Poste | Début |
|---|---|---|
Amaranth Medical, Inc.
 Amaranth Medical, Inc. Pharmaceuticals: MajorHealth Technology Amaranth Medical, Inc. develops and manufactures a technology platform for fully bioresorbable scaffolds. It operates as a holding company that engages in the development and manufacture of technology platform for fully bioresorbable scaffolds. Its proprietary bioresorbable technology platform holds great potential for both vascular and nonvascular applications. The company was founded by Freddy Yin Chiang Boey and Subbu S. Venkatraman in 2005 and is headquartered in Mountain View, CA. | Directeur/Membre du Conseil | - |
EDB Investments Pte Ltd.
 EDB Investments Pte Ltd. Investment ManagersFinance EDB Investments Pte Ltd (EDB Investments) is a Venture Capital firm founded in 1991. The firm is headquartered in Singapore. | Directeur/Membre du Conseil | 01/03/2023 |
Anciens postes connus de Heng Tong Choo
| Sociétés | Poste | Fin |
|---|---|---|
Maccine Pte Ltd.
 Maccine Pte Ltd. Pharmaceuticals: MajorHealth Technology Maccine is a Singapore-based preclinical contract research organization providing innovative discovery research and quality safety-assessment services to the global biotechnology and pharmaceutical industry. It offers creating translational value in the preclinical research space and significant investment in technology, people and science has ensured Maccine's position at the forefront of global preclinical research. Maccine is an established preclinical contract research organization providing innovative discovery support and regulatory safety assessment services. Operating on a collaborative partnering model, Maccine has developed a portfolio of in vivo assays in key therapeutic areas including Neurology, Psychiatry, Metabolic Disorders, Pain & Inflammation, Oncology, Musculoskeletal Disorders and Women's Health. Naturalistic models, clinical biomarkers and clinical technology platforms are employed to better represent the clinical disease state. The team is supported by significant investment in high-end technology and access to a world class scientific community. | Directeur/Membre du Conseil | 22/05/2014 |
EDB Investments Pte Ltd.
EDB Investments Pte Ltd. Investment ManagersFinance EDB Investments Pte Ltd (EDB Investments) is a Venture Capital firm founded in 1991. The firm is headquartered in Singapore. | Private Equity Investor | - |
Trireme Medical LLC
 Trireme Medical LLC Medical SpecialtiesHealth Technology Trireme Medical LLC develops and manufactures novel stent technology for the treatment of atherosclerotic disease. It offers coronary stent systems, balloon catheters, and percutaneous transluminal coronary angioplasty balloon catheters for the treatment of coronary and peripheral arterial disease. The company is focused on the United States and the emerging Asian markets. The company was founded by Eitan Konstantino and Feld Tanhum in 2005 and is headquartered in Pleasanton, CA, | Directeur/Membre du Conseil | - |
Inviragen, Inc.
 Inviragen, Inc. BiotechnologyHealth Technology Inviragen, Inc. developed life-saving vaccine to protect against infectious diseases worldwide. The company was founded by Dan T. Stinchcomb and Jorge Osorio in November 2003 and was headquartered in Fort Collins, CO. | Directeur/Membre du Conseil | - |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Directeur/Membre du Conseil | - |
Formation de Heng Tong Choo
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Imperial College London | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VANDA PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Trireme Medical LLC
Trireme Medical LLC Medical SpecialtiesHealth Technology Trireme Medical LLC develops and manufactures novel stent technology for the treatment of atherosclerotic disease. It offers coronary stent systems, balloon catheters, and percutaneous transluminal coronary angioplasty balloon catheters for the treatment of coronary and peripheral arterial disease. The company is focused on the United States and the emerging Asian markets. The company was founded by Eitan Konstantino and Feld Tanhum in 2005 and is headquartered in Pleasanton, CA, | Health Technology |
| Singapore Economic Development Board | Government |
EDB Investments Pte Ltd.
EDB Investments Pte Ltd. Investment ManagersFinance EDB Investments Pte Ltd (EDB Investments) is a Venture Capital firm founded in 1991. The firm is headquartered in Singapore. | Finance |
S*BIO Pte Ltd.
S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Health Technology |
Amaranth Medical, Inc.
Amaranth Medical, Inc. Pharmaceuticals: MajorHealth Technology Amaranth Medical, Inc. develops and manufactures a technology platform for fully bioresorbable scaffolds. It operates as a holding company that engages in the development and manufacture of technology platform for fully bioresorbable scaffolds. Its proprietary bioresorbable technology platform holds great potential for both vascular and nonvascular applications. The company was founded by Freddy Yin Chiang Boey and Subbu S. Venkatraman in 2005 and is headquartered in Mountain View, CA. | Health Technology |
Artisan Pharma, Inc.
 Artisan Pharma, Inc. Hospital/Nursing ManagementHealth Services Artisan Pharma, Inc. provides critical-care and hospital-based therapeutics to patients. The firm focuses on the clinical development of drugs in the field of critical care therapeutics throughout the world. The company was founded by Kazuhisa Tsuruta in 2006 and is headquartered in Waltham, MA. | Health Services |
Maccine Pte Ltd.
Maccine Pte Ltd. Pharmaceuticals: MajorHealth Technology Maccine is a Singapore-based preclinical contract research organization providing innovative discovery research and quality safety-assessment services to the global biotechnology and pharmaceutical industry. It offers creating translational value in the preclinical research space and significant investment in technology, people and science has ensured Maccine's position at the forefront of global preclinical research. Maccine is an established preclinical contract research organization providing innovative discovery support and regulatory safety assessment services. Operating on a collaborative partnering model, Maccine has developed a portfolio of in vivo assays in key therapeutic areas including Neurology, Psychiatry, Metabolic Disorders, Pain & Inflammation, Oncology, Musculoskeletal Disorders and Women's Health. Naturalistic models, clinical biomarkers and clinical technology platforms are employed to better represent the clinical disease state. The team is supported by significant investment in high-end technology and access to a world class scientific community. | Health Technology |
Inviragen, Inc.
Inviragen, Inc. BiotechnologyHealth Technology Inviragen, Inc. developed life-saving vaccine to protect against infectious diseases worldwide. The company was founded by Dan T. Stinchcomb and Jorge Osorio in November 2003 and was headquartered in Fort Collins, CO. | Health Technology |
